BOARD OF DIRECTORS

MARY PADBURY

Chair of the Board

Prior to retiring and joining Clinical Genomics, Ms. Padbury was a Partner and Vice Chairman of Ashurst, a global commercial law firm, and served as Chairman of Ashurst Australia for eight years before the firm’s full merger with Ashurst LLP in 2013. Ms. Padbury worked with Bristows, a UK full-service commercial law firm known mainly for its technology and intellectual property work. She currently serves as Chairman of the Board for Trans-Tasman IP Attorneys and is a member of the Board for the Macfarlane Burnet Institute for Medical Research and Public Health Ltd., Commonwealth Bank of Australia, and Victorian Legal Admissions Committee.
Ms. Padbury earned a BA LLB (Hons) from the Melbourne Law School and is a graduate of the Australian Institute of Company Directors.

ROBERT MAX MAWHINNEY

ROY DAVIS

Director

Roy Davis joined the Clinical Genomics Board in 2018 to support CG’s exciting growth opportunities in liquid biopsy and cancer testing. Mr. Davis spent 27 years with Johnson & Johnson and held positions of increasing responsibility including Group President, Company Group Chairman, Worldwide Franchise Chairman, and President of J & J Development Corporation. He also served as Managing Director and General Manager for Ortho Diagnostics in Europe, Japan and the Americas and was the founding President of Veridex (a Johnson & Johnson Company), one of the first organizations to introduce breakthrough technology in the field of circulating tumor cells. He is currently a Senior Advisor for Huron Global Management Consulting and its Innosight subsidiary and was previously an Innovations Advisory Board Member for the Cleveland Clinic. Mr. Davis received a Bachelor of Science from the University of Albany, SUNY and a Master of Science from Rensselaer Polytechnic Institute.

LAWRENCE LAPOINTE, PhD

PETER JOLLIE

Director

Peter Jollie AM is the past President of the Institute of Chartered Accountants in Australia and was also Australian Committee Chair of two multi-lateral Pacific Trade and Investment promotion organizations (PBEC & PECC). Mr. Jollie was appointed as a Member of the Order of Australia in 2000.

He has extensive experience as director and/or chairman of various listed and unlisted companies, including:

  • Coleman Greig (non-executive director, 2012 to present)
  • ASX Markets Supervision Pty Ltd (non-executive director, 2006 to 2010)
  • Downer EDI Limited (non-executive director and then Chairman, 2004 to 2010)
  • Travel.com.au Limited (non-executive director, 2002 to 2008)
  • Medical Research & Compensation Foundation (non-executive director, 2001 to 2006)
  • Defense Housing Authority (Chairman, 1997 to 2003)

Mr. Jollie is a Fellow of the Institute of Chartered Accountants in England and Wales (life member), a Fellow of Chartered Accountants in Australia and New Zealand, and a Fellow of the Australian Institute of Company Directors.

LAWRENCE LAPOINTE, PhD

KATHERINE KALIN

Director

Katherine Kalin has more than 25 years experience as a senior executive in the healthcare and professional services industries. Her healthcare industry expertise spans diagnostics, medical devices, and pharmaceuticals. Prior to joining Clinical Genomics, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for five years. Ms. Kalin held leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson (J&J) from 2002 to 2011. Prior to J&J, Ms. Kalin served as a Partner at McKinsey and Company, a global management consulting firm, where she negotiated and led consulting assignments, operating as a strategic advisor to senior executives. Earlier in her career, she was a Manager in Corporate Finance at Nomura International in the United Kingdom and Japan. From 2010-16, Katherine served as a member of the Summit Board of Education, New Jersey. Ms. Kalin received a BA in French from Durham University, UK, and an MBA from Harvard Business School.

LAWRENCE LAPOINTE, PhD

PAUL KELLY, MD, FRACP

Director

Paul Kelly, MD, FRACP, is a founding partner of One Ventures, a Sydney based venture capital firm providing human and investment capital into high growth companies based on transformative technologies. For more than two decades, Paul has assisted and led early-stage and mid-stage companies to transform ideas, technologies and products into sustainable successful businesses. From 2003-2006 he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), a leading provider of genetic testing services where he developed and managed major operational and strategic restructuring. He was CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company that he co-founded in 1995 to discover and commercialize novel gene-based targets. He positioned Gemini for one of the UK’s largest biotechnology IPOs in 2000, completed strategic acquisitions in Europe and North America and ultimately oversaw the company’s successful merger with Sequenom (Nasdq:SQNM) valuing Gemini at over $250M in 2001.

Before becoming a biotechnology executive, Dr. Kelly had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent’s Hospital, Sydney, Australia. While serving as a Research Physician at the Garvan Institute for Medical Research in Sydney, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of Charmhealth and FindMe technologies, and is a nonexecutive director of Agamatrix Inc., a US-based medical device company he co-founded. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Dr. Kelly is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Honors), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians.

LAWRENCE LAPOINTE, PhD

LAWRENCE LAPOINTE, PhD

Chief Executive Officer, Director, Co-Founder

Lawrence LaPointe has nearly two decades of senior management experience (General Manager, CTO, COO, CEO) developing, growing and selling companies in the field of cancer screening. Dr. LaPointe has an unbroken track record of increasing shareholder value each year of his career including co-founding Enterix Inc. which was built and sold for an enterprise value more than $50M. He has capital raising experience from private, venture and commercial funders totaling more than $40 million and global licensing and sales experience including US, EU, Asia, ANZ. Dr. LaPointe is a well published research scientist and holds numerous patents in the fields of biomarker discovery, cancer detection and molecular diagnostics. He holds a B.Sc. in Biology from Florida State University and a Ph.D. in Bioinformatics from Flinders University, Australia.

LAWRENCE LAPOINTE, PhD

ROBERT MAX MAWHINNEY

Director

Max Mawhinney was a co-founder and largest shareholder of Enterix Inc. in 1997 and is a co-founder and largest shareholder in Clinical Genomics Technologies. In addition to his experience in managing technology start-ups, Max was previously the founder and Managing Director of ICA Property, a company specialising in major industrial and commercial projects. ICA Property initiated a number of substantial development funds raising capital from major Australian institutional investors. Through ICA Property, Max was responsible for over $1billion in projects and has extensive experience in all aspects of business management and he has served on the Board of a number of Australian companies. Max was also a founding Director of the Property Industry Foundation, a charity set up to raise money to provide facilities for “kids on the streets” in Sydney. He was also a founding Director of the Urban Task Force, the major property industry lobby group. Max also has extensive farming interests.

ROBERT MAX MAWHINNEY

Social Icons

Facebook Twitter LinkedIn

Copyright © 2018 Clinical Genomics Technologies Pty Ltd. All Rights Reserved.